Cameron Gray - 03 Jan 2022 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Director
Signature
/s/ Cameron Gray by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
03 Jan 2022
Net transactions value
$0
Form type
4
Filing time
05 Jan 2022, 19:21:27 UTC
Next filing
16 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +10,000 $0.000000 10,000 03 Jan 2022 Common Stock 10,000 $12.28 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
F2 This option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date.